Oruka Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Oruka Therapeutics (ORKA) with an Overweight rating and $75 price target The firm says the company has a portfolio of “differentiated” antibodies with extended dosing intervals going after validated immunology targets. Oruka’s lead asset ORKA-001 is clinically validated by Skyrizi, which achieved $11.7B of sales in fiscal 2024 across four indications, the analyst tells investors in a research note. Piper says Oruka’s “catalyst-rich year” in 2026 “provides a compelling buying opportunity.”